Kaplan Fox & Kilsheimer LLP is investigating Cerebras Systems Inc. for possible securities violations following a sharp stock price drop. The decline occurred after Cerebras announced increased costs due to renting third-party data center capacity to meet demand, which lowered profit margins temporarily. The stock fell nearly 20% after the announcement. Investors who suffered losses or have relevant information are encouraged to contact the law firm. This investigation highlights concerns about the company's financial disclosures and operational strategy.
AGC Biologics has signed a multi-year commercial manufacturing agreement with a major pharmaceutical company for its new Yokohama facility, locking in half of the mammalian cell production capacity. The deal, worth hundreds of millions of dollars, co...
AGC Biologics has signed a multi-year commercial manufacturing contract valued at hundreds of millions of dollars with a major biopharma company for its new Yokohama facility. The contract covers production of five biopharmaceutical programs, securin...
AGC Biologics has secured a long-term commercial manufacturing contract with a global biopharma company for its new Yokohama facility, expected to generate hundreds of millions of dollars. The contract covers production of five biopharmaceutical prod...
Seagate Technology reported strong Q4 2026 results, beating earnings per share estimates with $5.71 and revenue of $3.63 billion, driven by high demand for data storage from the AI sector. The company showed solid financial health with a low debt-to-...
Audiera (BEAT) fell sharply by 24.29%, breaking below the $3 support level to a low of $2.4 before slightly recovering to around $2.76. The drop followed increased selling pressure with significant outflows in both futures and spot markets, indicatin...
